Cargando…

The Effect of Ursodeoxycholic Acid on Small Intestinal Bacterial Overgrowth in Patients with Functional Dyspepsia: A Pilot Randomized Controlled Trial

Functional dyspepsia (FD) is associated with small intestinal bacterial overgrowth (SIBO). Several animal studies have reported that ursodeoxycholic acid (UDCA) has antibacterial and anti-inflammatory effects in the intestine. We hypothesized that UDCA may be effective against dyspeptic symptoms and...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Bom-Taeck, Kim, Kwang-Min, Kim, Kyu-Nam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7284594/
https://www.ncbi.nlm.nih.gov/pubmed/32422942
http://dx.doi.org/10.3390/nu12051410
_version_ 1783544503713398784
author Kim, Bom-Taeck
Kim, Kwang-Min
Kim, Kyu-Nam
author_facet Kim, Bom-Taeck
Kim, Kwang-Min
Kim, Kyu-Nam
author_sort Kim, Bom-Taeck
collection PubMed
description Functional dyspepsia (FD) is associated with small intestinal bacterial overgrowth (SIBO). Several animal studies have reported that ursodeoxycholic acid (UDCA) has antibacterial and anti-inflammatory effects in the intestine. We hypothesized that UDCA may be effective against dyspeptic symptoms and SIBO in patients with FD. We conducted this randomized controlled trial to investigate the effects of UDCA in FD patients with SIBO. Twenty-four patients diagnosed with FD and SIBO based on lactulose breath test (LBT) were randomly assigned to either a UDCA treatment group or an untreated group. The treatment group received 100 mg of UDCA three times per day for two months; the untreated group was monitored for two months without intervention. After two months in both groups, we reevaluated LBT and FD symptoms using the Nepean dyspepsia index-K. FD symptoms in the UDCA-treated group were significantly reduced after two months compared with baseline and FD symptom scores between the UDCA-treated and untreated groups showed statistically significant differences after two months. In addition, the total methane gas levels for 90 minutes in LBT were significantly decreased after two months compared with baseline in the UDCA-treated group. In this preliminary exploratory study, we found that two months of UDCA treatment resulted in FD symptom improvement and reduced methane values during 90 minutes on the LBT, suggesting that methane-producing SIBO were associated with symptoms of dyspepsia and that UDCA was helpful in these patients. These findings need to be validated via large-scale controlled and well-designed studies.
format Online
Article
Text
id pubmed-7284594
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-72845942020-06-19 The Effect of Ursodeoxycholic Acid on Small Intestinal Bacterial Overgrowth in Patients with Functional Dyspepsia: A Pilot Randomized Controlled Trial Kim, Bom-Taeck Kim, Kwang-Min Kim, Kyu-Nam Nutrients Article Functional dyspepsia (FD) is associated with small intestinal bacterial overgrowth (SIBO). Several animal studies have reported that ursodeoxycholic acid (UDCA) has antibacterial and anti-inflammatory effects in the intestine. We hypothesized that UDCA may be effective against dyspeptic symptoms and SIBO in patients with FD. We conducted this randomized controlled trial to investigate the effects of UDCA in FD patients with SIBO. Twenty-four patients diagnosed with FD and SIBO based on lactulose breath test (LBT) were randomly assigned to either a UDCA treatment group or an untreated group. The treatment group received 100 mg of UDCA three times per day for two months; the untreated group was monitored for two months without intervention. After two months in both groups, we reevaluated LBT and FD symptoms using the Nepean dyspepsia index-K. FD symptoms in the UDCA-treated group were significantly reduced after two months compared with baseline and FD symptom scores between the UDCA-treated and untreated groups showed statistically significant differences after two months. In addition, the total methane gas levels for 90 minutes in LBT were significantly decreased after two months compared with baseline in the UDCA-treated group. In this preliminary exploratory study, we found that two months of UDCA treatment resulted in FD symptom improvement and reduced methane values during 90 minutes on the LBT, suggesting that methane-producing SIBO were associated with symptoms of dyspepsia and that UDCA was helpful in these patients. These findings need to be validated via large-scale controlled and well-designed studies. MDPI 2020-05-14 /pmc/articles/PMC7284594/ /pubmed/32422942 http://dx.doi.org/10.3390/nu12051410 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kim, Bom-Taeck
Kim, Kwang-Min
Kim, Kyu-Nam
The Effect of Ursodeoxycholic Acid on Small Intestinal Bacterial Overgrowth in Patients with Functional Dyspepsia: A Pilot Randomized Controlled Trial
title The Effect of Ursodeoxycholic Acid on Small Intestinal Bacterial Overgrowth in Patients with Functional Dyspepsia: A Pilot Randomized Controlled Trial
title_full The Effect of Ursodeoxycholic Acid on Small Intestinal Bacterial Overgrowth in Patients with Functional Dyspepsia: A Pilot Randomized Controlled Trial
title_fullStr The Effect of Ursodeoxycholic Acid on Small Intestinal Bacterial Overgrowth in Patients with Functional Dyspepsia: A Pilot Randomized Controlled Trial
title_full_unstemmed The Effect of Ursodeoxycholic Acid on Small Intestinal Bacterial Overgrowth in Patients with Functional Dyspepsia: A Pilot Randomized Controlled Trial
title_short The Effect of Ursodeoxycholic Acid on Small Intestinal Bacterial Overgrowth in Patients with Functional Dyspepsia: A Pilot Randomized Controlled Trial
title_sort effect of ursodeoxycholic acid on small intestinal bacterial overgrowth in patients with functional dyspepsia: a pilot randomized controlled trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7284594/
https://www.ncbi.nlm.nih.gov/pubmed/32422942
http://dx.doi.org/10.3390/nu12051410
work_keys_str_mv AT kimbomtaeck theeffectofursodeoxycholicacidonsmallintestinalbacterialovergrowthinpatientswithfunctionaldyspepsiaapilotrandomizedcontrolledtrial
AT kimkwangmin theeffectofursodeoxycholicacidonsmallintestinalbacterialovergrowthinpatientswithfunctionaldyspepsiaapilotrandomizedcontrolledtrial
AT kimkyunam theeffectofursodeoxycholicacidonsmallintestinalbacterialovergrowthinpatientswithfunctionaldyspepsiaapilotrandomizedcontrolledtrial
AT kimbomtaeck effectofursodeoxycholicacidonsmallintestinalbacterialovergrowthinpatientswithfunctionaldyspepsiaapilotrandomizedcontrolledtrial
AT kimkwangmin effectofursodeoxycholicacidonsmallintestinalbacterialovergrowthinpatientswithfunctionaldyspepsiaapilotrandomizedcontrolledtrial
AT kimkyunam effectofursodeoxycholicacidonsmallintestinalbacterialovergrowthinpatientswithfunctionaldyspepsiaapilotrandomizedcontrolledtrial